601607 上海医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.5447.7596.4945.5589.650
总资产报酬率 ROA (%)1.4792.5202.1021.8383.107
投入资产回报率 ROIC (%)2.4814.1943.5483.1465.510

边际利润分析
销售毛利率 (%)11.02610.72611.12912.03613.142
营业利润率 (%)3.8243.5062.9582.9463.886
息税前利润/营业总收入 (%)4.2903.9593.4523.2814.363
净利润/营业总收入 (%)2.9442.4592.1331.9853.014

收益指标分析
经营活动净收益/利润总额(%)86.18174.30094.447103.28880.311
价值变动净收益/利润总额(%)14.72535.6657.2854.7728.536
营业外收支净额/利润总额(%)-0.149-1.245-1.505-8.689-2.342

偿债能力分析
流动比率 (X)1.3421.3351.3631.3271.351
速动比率 (X)1.0380.9991.0541.0281.039
资产负债率 (%)61.46361.48962.14362.10560.632
带息债务/全部投入资本 (%)41.70743.27443.46742.10339.011
股东权益/带息债务 (%)132.520124.633124.672130.853149.257
股东权益/负债合计 (%)52.94452.93752.14052.05255.824
利息保障倍数 (X)9.1087.9786.4165.7487.708

营运能力分析
应收账款周转天数 (天)105.626102.47099.44196.60196.888
存货周转天数 (天)60.39259.94055.60555.88254.997